Cellebrite DI (CLBT) Set to Release Quarterly Earnings on Thursday

Key Points

• Cellebrite DI is scheduled to report Q3 2026 results before market open on November 12. Analysts expect earnings of $0.094 per share and revenue of $145.83 million.
• Analysts’ consensus rating is “Moderate Buy,” with an average price target of $16.70; five analysts rate the stock Buy and one rates it Sell.
• Company insiders sold 196,870 shares worth about $2.8 million over the past three months. CLBT shares opened at $12.43, within a 52-week range of $9.58 to $19.98.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of $0.0940 per share and revenue of $145.83 million for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $12.43 on Thursday. Cellebrite DI has a fifty-two week low of $9.58 and a fifty-two week high of $19.98. The firm has a market capitalization of $3.10 billion, a price-to-earnings ratio of 43.75, a PEG ratio of 1.88 and a beta of 1.06. The stock's 50-day simple moving average is $11.56 and its 200-day simple moving average is $13.36.

Wall Street Analyst Weigh In

CLBT has been the subject of a number of recent analyst reports. Needham & Company LLC lowered their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a "buy" rating for the company in a research note on Friday, August 14th. Weiss Ratings lowered shares of Cellebrite DI from a "sell (d+)" rating to a "sell (d)" rating in a research note on Thursday, August 27th. Lake Street Capital cut their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, August 14th. DA Davidson reaffirmed a "buy" rating and issued a $15.00 price target on shares of Cellebrite DI in a report on Tuesday, September 15th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating for the company in a research note on Friday, August 14th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $16.70.

Insider Buying and Selling at Cellebrite DI

In other Cellebrite DI news, CFO David Barter sold 12,134 shares of the stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $11.21, for a total transaction of $136,022.14. Following the sale, the chief financial officer directly owned 322,085 shares of the company's stock, valued at approximately $3,610,572.85. This trade represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CRO Marcus Jewell sold 12,562 shares of Cellebrite DI stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $11.24, for a total value of $141,196.88. Following the transaction, the executive owned 427,128 shares of the company's stock, valued at $4,800,918.72. The trade was a 2.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 196,870 shares of company stock valued at $2,797,143 in the last three months. Company insiders own 5.70% of the company's stock.

About Cellebrite DI

Cellebrite DI Ltd. NASDAQ: CLBT provides digital intelligence and digital forensics solutions that help organizations collect, preserve, analyze and manage data from mobile devices, computers, cloud environments and other digital sources. Its customers include law enforcement agencies, public safety organizations, government and intelligence bodies, military units, and corporate security and investigation teams.

The company's offerings include tools for accessing and extracting digital evidence, case and evidence management, and investigative analytics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.